Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 1059
Summary
- Conditions
- Melanoma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Care Provider, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01546571
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Craig Slingluff, M.D. University of Virginia Hospital
Get Well Soon